Open Access

A case report on efficacy of Abound™ for anti-EGFR antibody-associated skin disorder in metastatic colon cancer

  • Nobuhisa Matsuhashi1,
  • Takao Takahashi1,
  • Kenichi Nonaka1,
  • Kengo Ichikawa1,
  • Kazunori Yawata1,
  • Toshiyuki Tanahashi1,
  • Hisashi Imai1,
  • Yoshiyuki Sasaki1,
  • Yoshihiro Tanaka1,
  • Naoki Okumura1,
  • Kazuya Yamaguchi1,
  • Shinji Osada1 and
  • Kazuhiro Yoshida1Email author
World Journal of Surgical Oncology201412:35

https://doi.org/10.1186/1477-7819-12-35

Received: 8 September 2013

Accepted: 29 January 2014

Published: 11 February 2014

Abstract

Background

Panitumumab is a full human epidermal growth factor receptor (EGFR) monoclonal antibody, an agent for metastatic colorectal cancer therapy. One of the most general adverse events of anti-EGFR monoclonal antibody therapy is skin disorder. At the present time, although prophylaxis of skin disorder is important for continuation of cancer therapy, there are no effective precautionary treatments.

Case presentation

A 73-year-old male with sigmoid colon cancer and synchronous lung metastasis was treated with panitumumab, an alone anti-EGFR monoclonal antibody as the third-line therapy.

During the nine courses of the therapy, the response was stable disease (SD), but skin disorder gradually appeared obviously (CTCAE version 4.0: Grade 2). After 1 month of administration of Abound™, symptoms of the skin disorder improved (CTCAE version 4.0: Grade 1), thus the antibody therapy could be continued.

Conclusion

We report that Abound™ was apparently effective in the treatment for anti-EGFR antibody-associated skin disorder. In the future, Abound™ could be expected as an agent for skin disorder as one of the side effects of colorectal cancer therapy.

Keywords

AboundAnti-EGFR antibodySkin disorderColon cancer

Background

In recent years, remarkable progress has been made in chemotherapy for colorectal cancer. In particular, the treatment for advanced or metastatic colorectal cancer has dramatically improved owing to the development of FOLFOX and FOLFIRI therapies. Furthermore, the introduction of targeted therapy has made the treatment more effective and helpful for patients suffering from colorectal cancer. However, as an example of peripheral neuropathy, a serious major side effect of oxaliplatin (L-OHP), the control of adverse events is difficult for the continuation of cancer therapy. In addition, at the same time, the prevention of skin disorder associated with anti-epidermal growth factor receptor (EGFR) antibody therapy is important to continue the cancer therapy. However, at present, treatment associated with the skin disorder is mainly symptomatic.

Abound™ (ABBOTT JAPAN CO., LTD, Tokyo) constituted by a mixture of β-hydroxyl β-methylbutyrate, glutamine, and arginine (HMB/Gln/Arg). Abound™ previously showed activity for healing bed ulcers, increasing lean body mass (LBM) among patients with cancer cachexia [1, 2]. Therefore, our hypothesis considered whether Abound™ is effective for cancer patients with skin disorder. We report that Abound™ was effective for a non-resectable colorectal cancer patient treated with an anti-EGFR antigen panitumumab who had developed skin disorder.

Case presentation

A 74-year-old male with sigmoid colon cancer and synchronous lung metastasis (stage IV) underwent high anterior resection and D3 lymphadenectomy. The patient received 16 courses of FOLFOX and bevacizumab (BV) as first-line therapy, postoperatively. For the reason of disease progression, the patient was followed by BV and FOLFIRI as second-line therapy. The patient’s performance status (PS) went down to PS 1 in accordance with accumulation of the side effect of FOLFIRI therapy, but disease control indicated progression of the disease. Therefore, the patient was started on only panitumumab therapy, an anti-EGFR antigen, in order to wild type the Kras gene type.

An antibiotic agent, minocycline hydrochloride (minocycline), and an external preparation, dexamethasone, were administered form the start of the panitumumab therapy for prophylaxis of the skin disorder.

During the second course of the anti-EGFR antibody therapy, skin disorder appeared on the patient’s facial surfaces and gradually on other parts. The symptomatic treatment was continued; however, at the end of the ninth course of the anti-EGFR antibody therapy, the skin disorder was observed on both the lower limbs as well as on the face remarkably. Thus, AboundTM containing HMB/Gln/Arg was administered with two packs (48 g) a day. The skin disorder on both the lower limbs profoundly improved after 1 month of continuation of Abound™ (Figures 1a,b and 2a,b).
Figure 1

Before and after images of Abound TM treatment: face. (a) Before AboundTM was administered (CTCAE version 4.0: Grade 2). (b) After AboundTM was administered (CTCAE version 4.0: Grade 1). CTCAE, common terminology criteria for adverse events.

Figure 2

Before and after images of Abound™ treatment: lower limbs. (a) Before Abound™ was administered (CTCAE version 4.0: Grade 2). (b) After Abound™ was administered (CTCAE version 4.0: Grade 0). CTCAE, common terminology criteria for adverse events.

Discussion

Molecules of the EGFR family compose signal transduction pathways and play a major role in intracellular reaction processes [35]. New entities have been developed to target the pathway because EGFR has been observed in high frequency in non-small cell lung cancer (NSCLC) and colorectal or pancreatic cancer. EGFR tyrosine kinase inhibitors, including gefitinib and erlotinib, were launched as chemotherapy agents for NSCLC. Recently, cetuximab and panitumumab as EGFR monoclonal antigens have been made available for the treatment of colorectal cancer [69].

These agents are characteristically known to cause the side effect of frequent skin disorder, and thus the control of the skin disorder itself and its symptoms are very important for cancer therapy. From this point of view, skin disorder with inhibitors of the EGFR system can be used to continue the drug administration for cancer therapy, which is most important simultaneous with symptom control of the skin disorder [10]. In addition, with regards to erlotinib, correlation between the severity of skin disorder and the curative effect against cancer has shown that when the severity of skin disorder is higher, the curative effect is higher, and it has been suggested that cetuximab and panitumumab may demonstrate the same characteristics [11, 12].

At present, minocycline hydrochloride (minocycline) with steroidal agents are recognized as supportive treatment for the prevention of skin disorder with anti-EGFR antibody, utilized in various institutes, in accordance with the results of the skin toxicity evaluation protocol with panitumumab (STEPP) study [13].

In this case, we administered Abound™ containing HMB/Gln/Arg, and observed improvement of the skin disorder. HMB, a metabolite of leucine, is suggested to promote collagen deposition with modification of muscle protein degradation and to modulate inflammatory reaction by inhibiting the activity of NF-κB. Arginine is a semi-essential amino acid that can enhance immunity and wound healing by potentiating the cellulation process of fibroblasts. Glutamine is supposed to relate to the metabolic response of external injury and sepsis and to enhance gut immunity by affecting lymphocytes and intestinal epithelium cells, and has an effect on the improvement of gastrointestinal disorders for patients receiving anti-cancer chemotherapy. Since AboundTM is a dietary supplement, it is well tolerated, without any reported side effects. Abound™ has been shown to have efficacy on the nutritional management of cancer and HIV cachexia patients, and HMB/Gln/Arg supplementation can be important for those patients [2, 1416]. The HMB/Gln/Arg levels in advanced, metastatic, or recurrent cancer patients are considered to be low. Abound™, one pack of which contains 1,200 mg of HMB, 7,000 mg of glutamine, and 7,000 mg of arginine, can support balanced nutritional management, and in this case report we suggest that Abound™ may promote wound healing in skin disorder.

Conclusion

In the future, prospective studies of Abound™ in patients treated with anti-EGFR antibody is necessary, but our report indicates that Abound™ may have the potential to support nutritional status and to improve skin disorder. Thus, when larger studies can demonstrate the efficacy, Abound™ could provide an effective option for the management of side effects in colorectal cancer treatment.

Consent

Written informed consent was obtained from all patients enrolled in the investigation. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and the guidelines of the regional ethical committees of Zurich, Switzerland, and Basel, Switzerland.

Abbreviations

Arg: 

Arginine

BV: 

Bevacizumab

CTCAE: 

Common terminology criteria for adverse events

EGFR: 

Epidermal growth factor receptor

Gln: 

Glutamine

HMB: 

β-hydroxyl β-methylbutyrate

LBM: 

Lean body mass

L-OHP: 

Oxaliplatin

NSCLC: 

Non-small cell lung cancer

PS: 

Performance status

SD: 

Stable disease

STEPP: 

Skin toxicity evaluation protocol with panitumumab.

Declarations

Authors’ Affiliations

(1)
Surgical Oncology, Gifu University School of Medicine

References

  1. Berk L, James J, Schwartz A, Hug E, Mahadevan A, Samuels M, Kachnic L, RTOG: A randomized, double-blind, placebo-controlled trial of a β-hydroxyl β-methyl butyrate, glutamine, and argininemixture for the treatment of cancer cachexia (RTOG 0122). Support Care Cancer. 2008, 16: 1179-1188. 10.1007/s00520-008-0403-7.View ArticlePubMedGoogle Scholar
  2. Marcoraa S, Lemmeya A, Maddisona P: Dietary treatment of rheumatoid cachexia with b-hydroxy-b-methylbutyrate, glutamine andarginine: a randomised controlled trial. Clin Nutr. 2005, 24: 442-454. 10.1016/j.clnu.2005.01.006.View ArticleGoogle Scholar
  3. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010, 28 (31): 4697-4705. 10.1200/JCO.2009.27.4860.View ArticlePubMedGoogle Scholar
  4. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008, 26 (10): 1626-1634. 10.1200/JCO.2007.14.7116.View ArticlePubMedGoogle Scholar
  5. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010, 28 (31): 4706-4713. 10.1200/JCO.2009.27.6055.View ArticlePubMedGoogle Scholar
  6. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005, 6 (5): 279-286. 10.1016/S1470-2045(05)70102-9.View ArticlePubMedGoogle Scholar
  7. Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P, Köhne CH: Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol. 2006, 17 (3): 450-456. 10.1093/annonc/mdj084.View ArticlePubMedGoogle Scholar
  8. Personeni N, Hendlisz A, Gallez J, Galdon MG, Larsimont D, Van Laethem JL, Nagy N, Barette M, Paesmans M, Cardoso F, Bleiberg H: Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. Semin Oncol. 2005, 32 (6 Suppl 9): S59-S62.View ArticlePubMedGoogle Scholar
  9. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66 (8): 3992-3995. 10.1158/0008-5472.CAN-06-0191.View ArticlePubMedGoogle Scholar
  10. Su X, Lacouture ME, Jia Y, Wu S: Risk of high-grade skin rash in cancer patients treated with cetuximab – an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncol. 2009, 77 (2): 124-133. 10.1159/000229752.View ArticleGoogle Scholar
  11. Gatzemeier U, von Pawel J, Vynnychenko I, Zatloukal P, de Marinis F, Eberhardt WE, Paz-Ares L, Schumacher KM, Goddemeier T, O’Byrne KJ, Pirker R: First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol. 2011, 12 (1): 30-37. 10.1016/S1470-2045(10)70278-3.View ArticlePubMedGoogle Scholar
  12. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Störkel S, Schumacher KM, von Heydebreck A, Celik I, O'Byrne KJ: EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012, 13: 33-42. 10.1016/S1470-2045(11)70318-7.View ArticlePubMedGoogle Scholar
  13. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC: Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007, 25 (34): 5390-5396. 10.1200/JCO.2007.12.6987.View ArticlePubMedGoogle Scholar
  14. May PE, Barber A, D’Olimpio JT, Hourihane A, Abumrad NN: Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am J Sur. 2002, 183 (4): 471-479. 10.1016/S0002-9610(02)00823-1.View ArticleGoogle Scholar
  15. Williams JZ, Abumrad N, Barbul A: Effect of a specialized amino acid mixture on human collagen deposition. Ann Surg. 2002, 236 (3): 369-375. 10.1097/00000658-200209000-00013.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Clark RH, Feleke G, Din M, Yasmin T, Singh G, Khan FA, Rathmacher JA: Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. JPEN J Parenter Enteral Nutr. 2000, 24 (3): 133-139. 10.1177/0148607100024003133.View ArticlePubMedGoogle Scholar

Copyright

© Matsuhashi et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement